Long-Term Outcomes After Hepatectomy for Alveolar Echinococcosis in Immunosuppressed Patients

Long-term outcomes after hepatectomy for alveolar echinococcosis (AE) in immunosuppressed patients remain poorly investigated. This study evaluated recurrence rates and recurrence-free/overall survivals (RFS/OS) after AE resection in immunocompromised and immunocompetent patients. Consecutive patients operated for liver AE in two university hospitals were retrospectively collected (2000–2021). Immunosuppressed patients were defined as patients who had a reduced ability to fight infection due to certain diseases or treatments. 195 patients had hepatectomy for liver AE. Preoperative albendazole was given in 111 cases (57%). Fifty-two patients (27%) were considered immunosuppressed. Patients in the immunosuppressed and immunocompetent cohorts had similar preoperative characteristics. Recurrences occurred in 10 patients (immunosuppressed group: 4, non-immunosuppressed group: 6) within a median follow-up of 58 months (95%CI 48–68). No significant differences in RFS and OS were found between the immunosuppressed and immunocompetent groups (212 vs. 206 months, p = 0.625 and 236 vs. 210 months, p = 0.282). Two-year recurrence rates were 0% in the immunosuppressed cohort and 1% (1/142) in the immunocompetent patients (p = 0.466). Absence of preoperative albendazole and lesion size were predictive of recurrence after hepatectomy. Immunosuppression was not found to be a risk factor for recurrence (HR 1.4, p = 0.626). In this bicentric study, immunocompromised patients did not have significantly different recurrence rates, RFS, and OS than immunocompetent patients.